SURMOUNT-5 was a 72-week, open-label, Phase 3b randomised trial of 751 adults with obesity but without diabetes, comparing maximum-tolerated tirzepatide (10 or 15 mg) against maximum-tolerated semaglutide (1.7 or 2.4 mg)
The Wegovy pill is oral semaglutide at 25 mg a day, licensed for weight loss in the UK from June 2026
Obesity is a chronic, systemic disease driven by excess adiposity that can cause severe organ dysfunction and lifethreatening complications (for example, stroke, cardiovascular disease, type 2 diabetes, depression, and certain cancers) [1,2]
Due to its toxicity, the EPA has restricted the use of Paraquat and it is currently banned in over 30 countries